GOZILA Study: Liquid Biopsy-Guided Treatment Doubles Survival in Advanced Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a top precision oncology company, has shared new findings in the renowned journal *Nature Medicine* from the SCRUM-Japan GOZILA study. The study highlights that using the Guardant360® CDx liquid biopsy for choosing targeted therapy can considerably enhance survival in patients with advanced cancer.

Conducted by National Cancer Center Hospital East in Kashiwa, Japan, the extensive study involved 4,037 patients with advanced cancer. The main focus was to assess the impact of personalized treatment informed by the Guardant360 CDx test, which evaluates 74 genes linked to cancer. Findings revealed that 24% of the participants were able to receive tailored targeted therapies based on a thorough genomic analysis from the test. Significantly, those who received such targeted treatment lived almost twice as long as those who did not.

Dr. Yoshiaki Nakamura, chief of the International Research Promotion Office at National Cancer Center Hospital East, commented on the advantages of liquid biopsies over traditional tissue biopsies. Liquid biopsies are less invasive, allow for repeated testing, and can assess cancer characteristics from multiple body areas simultaneously. Dr. Nakamura emphasized that the GOZILA study is pioneering in demonstrating the survival benefits of liquid biopsy-informed personalized cancer treatment on a large scale and across various cancer types, potentially revolutionizing cancer treatment approaches.

By selecting therapies based on liquid biopsy results, researchers could identify effective targeted treatments that traditional methods might miss. The study tracked the treated patients' progress, analyzing their response to the treatment and their survival times. Results showed that patients who received targeted therapies based on liquid biopsy results had a median survival of 18.6 months, in contrast to 9.9 months for those who did not.

Dr. Craig Eagle, Guardant Health's chief medical officer, stated that the GOZILA study significantly bolsters the evidence supporting the clinical utility of the Guardant360 CDx liquid biopsy in guiding therapy selection for advanced cancer. The study's results reaffirm that personalized therapy, directed by liquid biopsy, can considerably extend patient survival across a diverse range of tumor types.

Guardant360 CDx, the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors, provides oncologists with genomic profiling results from a blood sample in under seven days. This enables the pairing of patients with suitable targeted therapies. The test identifies actionable biomarkers recommended by guidelines across all four major alteration classes, evaluating 74 genes. Guardant360 CDx serves as a companion diagnostic (CDx) for multiple targeted therapies in non-small cell lung cancer (NSCLC) and is unique in its FDA approval to identify patients eligible for breast cancer therapy targeting ESR1 mutations.

Guardant Health, a leading precision oncology company founded in 2012, is dedicated to enhancing patient care and advancing new cancer therapies through its advanced blood and tissue tests, real-world data, and AI analytics. Guardant's innovations aim to improve outcomes at all stages of cancer care, from early detection and monitoring for recurrence to treatment selection for advanced cancer patients.

For more details, visit guardanthealth.com and follow Guardant Health on LinkedIn, X (Twitter), and Facebook.